Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703806 | 1.00 | HSD17B10 (0.38) | HSD17B10CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL16343345 | 0.84 | CYP3A4 (0.33) | HSD17B10CYP1A2CYP2C19CYP2C9CYP2A6 | |
| SCHEMBL1423533 | 0.84 | CYP2A6 (0.34) | HSD17B10CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL16343301 | 0.82 | — | — | |
| SCHEMBL16343275 | 0.82 | NCF1 (0.33) | CYP1A2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL2145669 | 0.82 | MEN1 (0.34) | GAA | |
| SCHEMBL16343144 | 0.81 | — | — | |
| SCHEMBL16343293 | 0.80 | NPC1 (0.32) | ALDH1A1KDM4EMAPTCYP2D6HPGD | |
| SCHEMBL16343218 | 0.80 | KDM4E (0.32) | KDM4E | |
| SCHEMBL3680960 | 0.80 | CYP2D6 (0.48) | CYP1A2CYP2C19CYP2C9TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106928061-B | Continuous process for the carbonylation of ethylene | 璐彩特国际英国有限公司 | 2020-08-28 | — | — | CN | claimed |
| EP-2794548-B1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INT UK LTD (GB) | 2019-05-15 | — | — | EP | claimed |
| US-9382190-B2 | Continuous process for the carbonylation of ethylene | LUCITE INTERNATIONAL UK LIMITED (GB) | 2016-07-05 | — | — | US | claimed |
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-04-09 | — | — | US | claimed |
| EP-2007703-B1 | METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INT UK LTD (GB) | 2013-12-18 | — | — | EP | claimed |
| US-8445711-B2 | Metal complexes | LUCITE INTERNATIONAL UK LIMITED (GB) | 2013-05-21 | — | — | US | claimed |
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-08-05 | — | — | US | claimed |
| EP-2167232-A1 | A PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | Lucite International UK Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| US-20090312561-A1 | METAL COMPLEXES | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-12-17 | — | — | US | claimed |
| WO-2009010782-A1 | A PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-01-22 | — | — | WO | claimed |
| EP-2007703-A1 | METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Lucite International UK Limited (GB) | 2008-12-31 | — | — | EP | claimed |
| WO-2007119079-A1 | METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2007-10-25 | — | — | WO | claimed |
| US-11958810-B2 | Preparation of optionally substituted dihydroisoquinolines | BASF SE (DE) | 2024-04-16 | — | — | US | disclosed |
| US-11613549-B2 | Bromination of pyridine derivatives | BASF SE (DE) | 2023-03-28 | — | — | US | disclosed |
| EP-3743416-B1 | HALOGENATION OF PYRIDINE DERIVATIVES | BASF SE (DE) | 2023-03-15 | — | — | EP | disclosed |
| US-11591312-B2 | Halogenation of pyridine derivatives | BASF SE (DE) | 2023-02-28 | — | — | US | disclosed |
| EP-1713582-A1 | A CATALYST SYSTEM | Lucite International UK Limited (GB) | 2006-10-25 | — | — | EP | disclosed |
| EP-1651587-A1 | PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Lucite International UK Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005079981-A1 | A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005003070-A1 | PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958810-B2 | Preparation of optionally substituted dihydroisoquinolines | SDHA, SDHB, QDPR | HSD17B10 1013/4885CYP1A2 60/4885CYP2C19 87/4885 |
| US-11591312-B2 | Halogenation of pyridine derivatives | CYP2F1, CYP4F2, FLI1 | HSD17B10 3499/4885CYP1A2 11/4885CYP2C19 26/4885 |
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | SCD, ELOVL6, ALK | HSD17B10 841/4885CYP1A2 290/4885CYP2C19 669/4885 |
| US-11613549-B2 | Bromination of pyridine derivatives | NDUFV2, NDUFV1, NDUFV3 | HSD17B10 2118/4885CYP1A2 24/4885CYP2C19 104/4885 |
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | ALOX5, ACSL5, ELOVL5 | HSD17B10 868/4885CYP1A2 182/4885CYP2C19 172/4885 |
| US-20090312561-A1 | METAL COMPLEXES | MLX, PICALM, AP2M1 | HSD17B10 4677/4885CYP1A2 2170/4885CYP2C19 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.